Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heidi Christ-Schmidt

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Trials (London, England)|May 21, 2010
Some practical problems in implementing randomizationMatt Downs, Kathryn Tucker, Heidi Christ-Schmidt, et al.
European Journal of Heart Failure|October 14, 2015
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitorsBertram Pitt, George L Bakris, David A Bushinsky, et al.
Plos Medicine|December 2, 2005
Are racial and ethnic minorities less willing to participate in health research?David Wendler, Raynard Kington, Jennifer Madans, et al.
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Lancet (London, England)|August 19, 2007
Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled studyHarvey L Levy, Andrzej Milanowski, Anupam Chakrapani, et al.
The New England Journal of Medicine|June 25, 2011
Bardoxolone methyl and kidney function in CKD with type 2 diabetesPablo E Pergola, Philip Raskin, Robert D Toto, et al.
American Journal of Medical Genetics. Part A|October 22, 2008
Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaPhillip Lee, Eileen P Treacy, Eric Crombez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
The Journal of Pediatrics|March 6, 2009
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled studyFriedrich K Trefz, Barbara K Burton, Nicola Longo, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Trials (London, England)|May 21, 2010
Some practical problems in implementing randomizationMatt Downs, Kathryn Tucker, Heidi Christ-Schmidt, et al.
European Journal of Heart Failure|October 14, 2015
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitorsBertram Pitt, George L Bakris, David A Bushinsky, et al.
Plos Medicine|December 2, 2005
Are racial and ethnic minorities less willing to participate in health research?David Wendler, Raynard Kington, Jennifer Madans, et al.
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Lancet (London, England)|August 19, 2007
Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled studyHarvey L Levy, Andrzej Milanowski, Anupam Chakrapani, et al.
The New England Journal of Medicine|June 25, 2011
Bardoxolone methyl and kidney function in CKD with type 2 diabetesPablo E Pergola, Philip Raskin, Robert D Toto, et al.
American Journal of Medical Genetics. Part A|October 22, 2008
Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaPhillip Lee, Eileen P Treacy, Eric Crombez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
The Journal of Pediatrics|March 6, 2009
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled studyFriedrich K Trefz, Barbara K Burton, Nicola Longo, et al.
Pageof 1